SJ-300

• Description :

  SJ-300 is a potent and selective, orally active and brain-penetrat DKK3-LRP1 interaction inhibitor. SJ-300 restores Aβ clearance in AD models. SJ 300 binds to mLRPIV with a Kd of 7.9 μM, inhibits the DKK3 mLRPIV complex with an IC50 of 3.2 μM, and does not disrupt the binding of Aβ to LRP1. SJ 300 rescues cognitive function and ameliorates neuropathology (Aβ plaque reduction ≈ 73.3 %) in vivo. SJ 300 can be employed for research in Alzheimer’s disease[1].

• UNSPSC :

  12352005

• Target :

  Amyloid-β; LDLR; Wnt

• Related Pathways :

  Metabolic Enzyme/Protease; Neuronal Signaling; Stem Cell/Wnt

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Smiles :

  FC1=CC=C(N2N=C(C)C(CNC3CCN(C4CC4)CC3)=C2C)C=C1

• Molecular Formula :

  C20H27FN4

• Molecular Weight :

  342.45

• References & Citations :

  [1]Yang R, et al. DKK3-LRP1 complex and a chemical inhibitor regulate Aβ clearance in models of Alzheimer's disease. Sci Adv. 2025 Nov 7;11 (45) :eadz2099.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1210357-06-4]